Generic Name and Formulations:
Desonide 0.05%; crm; lotion.
Galderma Laboratories, Inc.
Indications for DESOWEN:
Apply a thin film to affected areas 2–3 times daily; discontinue when control is achieved. Do not occlude.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Treat infection if present; discontinue if infection persists or worsens. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, stinging, irritation, contact dermatitis, condition worsened, skin peeling, itching, intense transient erythema, dryness/scaliness; HPA axis suppression (esp. in children).
Crm—15g, 60g; Lotion—2oz, 4oz
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Congress Passes Bill to Fight Opioid Crisis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure